1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers 
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Huntington’s Disease
2.1 What Are the Causes And Risk Factors Of Huntington’s Disease?
2.1.1 Risk Factors
2.1.1.1 Alcohol Intake
2.1.1.2 Pneumonia:
2.1.1.3 Stress
2.2 Symptoms of Huntington’s Disease
2.2.1 Symptoms in Adult Onset
2.2.2 Movement Disorders
2.2.3 Cognitive Disorders
2.2.4 Psychiatric Disorders
2.2.5 Symptoms in Juvenile Onset
2.2.6 Behavioural Changes:
2.3 Diagnosis of Huntington’s Disease
2.3.1 Neurological Tests:
2.3.2 Brain Function and Imaging Tests:
2.3.3 Genetic Testing:
2.3.4 Psychiatric Tests:
2.3.5 Test in Pregnancy:
2.3.6 Preimplantation Genetic Diagnosis:
2.4 Treatment of Huntington’s Disease
2.4.1 Medications for Movement Disorders:
2.4.2 Medications for Psychiatric Disorders:
2.4.3 Psychotherapy
2.4.4 Speech Therapy
2.4.5 Physical Therapy
2.4.6 Occupational Therapy
2.5 Epidemiology of Huntington’s Disease
2.6 Social and Economic Burden
2.6.1 Mortality
2.6.2 Morbidity
2.6.3 Economic Impact
2.7 Introduction to the Global Huntington’s Disease Market

3. Global Huntington’s Disease Market Size And Forecast By Drug Class
3.1 Market Segmentation by Application
3.2 Global Antidopaminergics Market
3.2.1 Market Overview
3.2.2 Market Size and Forecast
3.3 Global Antipsychotics Market
3.3.1 Market Overview
3.3.2 Market Size and Forecast
3.4 Global Anticonvulsants Market
3.4.1 Market Overview
3.4.2 Market Size and Forecast
3.5 Global Antidepressants Market
3.5.1 Market Overview
3.5.2 Market Size and Forecast
3.6 Global Other Huntington’s Disease Drugs Market
3.6.1 Market Overview
3.6.2 Market Size and Forecast

4. Leading Drugs in Global Huntington’s Disease Market, 2017
4.1 Xenazine (tetrabenazine)
4.2 Austedo (Deutetrabenazine)
4.3 Clozapine
4.4 Haloperidol
4.5 Abilify
4.6 Risperdal

5. Leading National Markets Forecast 2017-2028
5.1 Geographical Breakdown of Global Huntington’s Disease Drugs Market, 2016
5.2 Huntington’s Disease Drugs Market in the Americas, 2016
5.3 Huntington’s Disease Drugs Market in the EU5, 2016
5.3.1 Market Forecast of the EU5 Countries, 2017-2028
5.3.2 The UK
5.3.3 Germany
5.3.4 France
5.3.5 Spain
5.3.6 Italy
5.3.7 Huntington’s Disease Drugs Market in the Rest of Europe, 2016
5.4 Huntington’s Disease Drugs Market in the Rest of the World, 2016
5.4.1 Japan
5.4.2 China
5.4.3 Russia

6. Qualitative Analysis of the Huntington’s Disease Market
6.1 Market Growth Drivers
6.1.1 Unmet Medical Need
6.1.2 Special Regulatory Provisions for Rare Diseases
6.1.3 Designated ICD-10 Code
6.1.4 Increased investment in R&D
6.1.5 Alternative Therapies
6.2 Market Challenges
6.2.1 Poor Diagnosis Rates
6.2.2 Limited Patient Population
6.2.3 Stringent Regulatory Guidelines
6.2.4 Alternative programs for management of mental disorders
6.3 Market Trends
6.3.1 Advances in Biomedical Sciences
6.3.2 Focus on Regenerative Therapies for Mental Disorders
6.3.3 Rising Public Interest Toward Mental Health
6.3.4 Novel Mechanisms Targeted by Pipeline Candidates
6.3.5 Emergence of First-in-class Pipeline Molecules

7. Pipeline Molecules
7.1 Promising Potential Pipeline Molecules
7.1.1 Phase III Molecules
7.1.1.1 Tetrabenazine (Xenazine)
7.1.1.2 Deutetrabenazine (Austedo)
7.1.1.3 PRIDOPIDINE
7.1.2 Phase II Molecules
7.1.2.1 Laquinimod
7.1.2.2 PBT2
7.1.2.3 VX15 (SIGNAL)
7.1.2.4 PDE10A Inhibitor
7.1.2.5 Deep Brain Stimulation (DBS)
7.1.2.6 Cysteamine (RP103)
7.1.3 Phase I Molecules
7.1.3.1 Antisense Oligonucleotide Huntingtin Lowering Drug
7.1.4 Phase Pre-Clinical R&D
7.1.4.1 Pre- Cell/HD Cell
7.1.4.2 AAV-SHRNA
7.1.4.3 Zinc Finger DNA-Binding Protein (ZFP)
7.1.4.4 HDAC Inhibitor
7.1.4.5 KMO Inhibitor

8. Leading Companies in Global Huntington’s Disease Market, 2017
8.1 Hoffmann-La Roche Ltd.
8.1.1 SWOT Analysis:
8.2 H. Lundbeck
8.2.1 Business Strategy:
8.2.2 SWOT Analysis:
8.3 Teva Pharmaceutical Industries Ltd.
8.3.1 Business Strategy:
8.3.2 SWOT Analysis:
8.4 Prana Biotechnology
8.5 Sangamo Therapeutics Inc.
8.6 Horizon Pharma Plc.
8.6.1 Revenue from Business Units:
8.6.2 Business Strategy:
8.6.2.1 Key Developments:
8.6.2.2 SWOT Analysis:
8.7 Omeros Corp.
8.7.1 SWOT Analysis:
8.8 Valeant Pharmaceuticals International Inc.
8.8.1 Business strategy:
8.8.2 SWOT Analysis

9. Executive Summary and Recommendations

10. Glossary
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Figures
Figure 1.1 Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.1 Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.2 Global Huntington's Disease Market Segmentation by Drug Class (% Share)
Figure 3.1 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.2 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.3 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.4 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.5 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.6 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 5.1 Global Huntington's Disease Drugs Market Segmentation by Region/Country
Figure 5.2 Global Huntington's Disease Drugs Market by Region: Revenue ($m)
Figure 5.3 Global Huntington's Disease Drugs Market by Region: Market Share 2016 (%)
Figure 5.4 Global Huntington's Disease Drugs Market by Region: AGR 2017-2028 (%)
Figure 5.5 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Figure 5.6 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017 (%)
Figure 5.7 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2022 (%)
Figure 5.8 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2027 (%)
Figure 5.9 Huntington's Disease Drugs Market in the US: 2016 Market Share %
Figure 5.10 Huntington's Disease Drugs Market in the US: 2016 Revenue ($m), Market Share %
Figure 5.11 Huntington's Disease Market Forecast in the US 2017-2028: Revenue ($m), AGR (%)
Figure 5.12 Huntington's Disease Drugs Market in the EU5 2016: Global Market Share (%)
Figure 5.13 Huntington's Disease Drugs Market in the EU5 Countries 2016: Market Share (%)
Figure 5.14 Huntington's Disease Drugs Market in the EU5 Countries 2028 Market Share (%)
Figure 5.15 Huntington's Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2017-2028
Figure 5.16 Global Huntington's Disease Drugs Market Forecast in The UK 2017-2028: Revenue ($m), AGR (%)
Figure 5.17 Global Huntington's Disease Drugs Market Forecast in Germany 2017-2028: Revenue ($m), AGR (%)
Figure 5.18 Global Huntington's Disease Drugs Market Forecast in France 2017-2028: Revenue ($m), AGR (%)
Figure 5.19 Global Huntington's Disease Drugs Market Forecast in Spain 2017-2028: Revenue ($m), AGR (%)
Figure 5.20 Global Huntington's Disease Drugs Market Forecast in Italy 2017-2028: Revenue ($m), AGR (%)
Figure 5.21 Huntington's Disease Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2017-2028
Figure 5.22 Huntington's Disease Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2017-2028
Figure 8.1: Roche: Sales 2016
Figure 8.2: Roche: Sales 2016
Figure 8.3: H. Lundbeck: SWOT Analysis 2016
Figure 8.4 Teva: SWOT Analysis 2016
Figure 8.5 Horizon Revenue by Business Unit
Figure 8.6 Horizon: Drugs under Orphan Business Unit:
Figure 8.7 Horizon Drugs under Primary Care Unit:
Figure 8.8 Horizon: Drugs under Rheumatology Business Unit:
Figure 8.9 Horizon SWOT Analysis
Figure 8.10 Omeros Corp: SWOT Analysis
Figure 8.11 Valeant SWOT Analysis
Figure 9.1 Global Huntington's Disease Market Forecast 2017-2028: Revenue ($m), AGR (%)

List of Tables
Table 1.1 Example of Huntington's Disease Market by Regional Market Forecast 2017-2028 (US$m, AGR %, Cumulative)
Table 2.1: Prevalence of Huntington's Disease by Geography 2015
Table 2.2: Incidence of Huntington's Disease by Geography 2015
Table 3.1 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.2 Global Antidopaminergics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.3 Global Antipsychotics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.4 Global Anticonvulsants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.5 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.6 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 5.1 Global Huntington's Disease Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 5.2 Global Huntington's Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.3 Global Huntington's Disease Drugs Market by Region: AGR 2017-2028 (%)
Table 5.4 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Table 5.7 Global Huntington's Disease Drugs Market Forecast in the Americas: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.8 Global Huntington's Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.9 Huntington's Disease Drugs Market in the EU5, 2017
Table 5.10 Huntington's Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.11 Huntington's Disease Drugs Market Forecast in UK: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.12 Huntington's Disease Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.13 Huntington's Disease Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.14 Huntington's Disease Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.15 Huntington's Disease Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.16 Huntington's Disease Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.17 Huntington's Disease Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease
Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease (Continued)
Table 8.1:Roche: Overview 2016
Table 8.2: H. Lundbeck: Overview 2016
Table 8.3: Teva: Overview 2016
Table 8.4 Prana: Overview 2016
Table 8.5: Sangamo: Overview 2016
Table 8.6: Horizon: Overview 2016
Table 8.7: Omeros: Overview 2016
Table 8.8: Valeant: Overview 2016